Thomas Pike

CEO and Chairman of the Board at Fortrea Holdings Inc

Board

Since June 29, 2023

Age

64 years

Education

Earned his Bachelor of Science in Accounting from the University of Delaware.

Tenure

Joined FTRE on June 29, 2023 as Chief Executive Officer and Chairman of the Board following the company's spin-off.

Also at Fortrea Holdings Inc

Jill McConnell

Chief Financial Officer (CFO)

Mark Morais

COO and President, Clinical Services

Robert Parks

Chief Accounting Officer (CAO)

About

Thomas Pike, 64 years old , has built a distinguished career marked by over 30 years of experience in the industries of healthcare, technology services, and consulting. He earned his Bachelor of Science in Accounting from the University of Delaware , which laid the foundation for his impactful journey in several high-profile leadership roles.

Before his current role at FTRE, he accumulated extensive expertise holding executive titles at renowned organizations including McKinsey & Company, where he gained foundational management consulting experience, and Accenture, where he served as Chief Risk Officer, Managing Director, Global COO, and Chief Strategy Officer during pivotal moments such as the company’s IPO. His notable tenure at Quintiles Transnational Holdings, Inc. further highlighted his leadership capabilities, driving significant corporate growth and ethical recognition such as the World’s Most Ethical Companies awards.

In his most recent strategic career move, he joined Fortrea (FTRE) on June 29, 2023, stepping into the role of CEO and Chairman of the Board in connection with the company’s spin-off. This new chapter leverages his deep expertise in mergers and acquisitions, strategic development, and public company operations, positioning him to drive forward the company’s vision and growth. His ongoing board membership at Martin Marietta Materials, Inc. further complements his extensive leadership portfolio.

$FTRE Performance Under Thomas Pike

Past Roles

Organization	Role	Date Range	Details
Labcorp	President and CEO, Drug Development, Clinical Development, and Commercialization Services	Jan 2023 - Fortrea spin-off	Led the spin-off of Fortrea from Labcorp
Quintiles Transnational Holdings, Inc.	CEO, Board Member, and former Vice Chairman	N/A	Led a successful IPO and launched Q2 Solutions
Various Healthcare & Technology Services Companies	Co-founder, Advisor, Director	2017-2023	Focused on patients and clinical research sites
Martin Marietta Materials, Inc.	Board Member	2019 - [Stepped Down]**	Stepped down to focus on FTRE leadership
Accenture	Multiple executive roles (Chief Risk Officer, Managing Director, Global Chief Operating Officer, Chief Strategy Officer)	N/A	22-year career; participated in Accenture's IPO in July 2001
McKinsey & Company	Employee	N/A	Earlier in his career

Fixed Compensation

Data from FY 2023

Component Name	Amount	Payment Schedule	Additional Details
Base Salary	$1,100,000	Annual	Fixed annual salary.
Sign-On Equity Grant	$4,000,000	Vesting as per RSU schedule	Time-vested RSUs.
Initial Equity Grant	$20,000,000	Granted post spin-off (Aug 17, 2023)	Includes RSUs and stock options.
Guaranteed Bonus	$1,100,000	Annual	100% of base salary as per contract.
Supplemental Long-Term Disability Insurance	$2,332	Annual (paid by company)	Company-paid insurance.
401(k) Contributions	$10,577	Annual	Company match to 401(k) plan.

Performance Compensation

Data from FY 2023

Performance Compensation Components

Component	Target Amount	Threshold Amount	Max Amount	Weights	Evaluation Period	Vesting Schedule	Performance Metrics Details	Additional Details
Annual Target Bonus	$1,650,000	$1,100,000	N/A	N/A	Labcorp Bonus Plan (Jan 1, 2023 - Jun 30, 2023) and Fortrea Bonus Plan (Jul 1, 2023 - Dec 31, 2023)	N/A	Based on combined business performance factors and individual performance modifiers; specifics not disclosed	Guaranteed minimum payout is 100% of base salary